55results about "CD71" patented technology

Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase IIα and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

The invention mainly belongs to the technical field of tumor immunology, and particularly relates to a human urinary bladder carcinoma marker AG-CD71 and a monoclonal antibody ABC71 for preventing AG-CD71. The human urinary bladder carcinoma marker AG-CD71 provided by the invention is an abnormal glycosylated transferrin receptor TFRC; the abnormal glycosylated transferrin receptor TFRC refers tothat the TFRC carriers a saccharide structure Fucal-4(GlcNAcb1-3) as an epitope; the invention provides an antibody for the human urinary bladder carcinoma marker AG-CD71; the antibody is a specific monoclonal antibody ABC71 for preventing the human urinary bladder carcinoma marker AG-CD71; the monoclonal antibody is secreted from a hybridoma cell strain of which the preservation number is CGMCC No.14312. Cell and histology levels show that the ABC71 is capable of specifically recognizing human urinary bladder carcinoma cells and human urinary bladder carcinoma tissue. The monoclonal antibodyABC71 for preventing the human urinary bladder carcinoma has an intense positive reaction with human urinary bladder carcinoma tissue and has a negative reaction with normal human urinary bladder tissue.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

The present invention is directed to a method for detecting a mammal's prior exposure to radiation or radiomimetic agents. Labeled antibodies are employed to determine the quantity of transferrin receptors on the red blood cells of the mammal. The quantity of transferrin receptors on the red blood cells of the mammal is correlated to the mammal's prior exposure.

The present letter invention provides an engineered AAV capsid in which at least one protein on the capsid is modified to include an n-mer motif that promotes transduction of the capsid into the central nervous system (CNS) by interaction with a transferrin receptor. Further embodiments provide a carrier system comprising one or more carriers encoding an AAV capsid and a method of delivering a cargo to a CNS. The methods comprise administering an AAV capsid according to embodiments described herein in vivo or in vitro, and the AVV capsid comprises one or more carrier molecules.

Described herein are compositions and methods for selective depletion of target molecules using a recyclable CDP-receptor-binding mediated complex to elicit endocytosis and cellular degradation of the target. Exemplary compositions containing a peptide, such as a CDP peptide, that bind a transferrin receptor can be linked to a peptide that binds a target molecule. Such compositions can be used to selectively recruit the target molecule to endosomes via transferrin receptor-mediated endocytosis of the composition and the bound target molecule. Once inside the endosome, the acidic pH can lead to release of the target molecule from the composition due to pH-dependent binding of the composition for the target molecule, and the transferrin receptor portion is recycled back to the cell surface for “reloading”. The target molecule can then be trafficked into lysosomes wherein it is degraded.

The present invention relates to peptide ligands, such as bicyclic peptide ligands, specific for transferrin receptor 1 (TfR1). The invention also includes pharmaceutical compositions comprising said peptide ligands and the use of said peptide ligands and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.

The present invention relates to a method of selecting a polypeptide for display on a genetic display system according to activity, comprising the steps of: displaying the polypeptide on the genetic display system, screening a system for binding to a target, and selecting a member binding to the target; cloning a nucleic acid encoding the polypeptide from a member of the display system, and expressing the nucleic acid in an expression system to produce the polypeptide, or sequencing the polypeptide from a member of the display system, and cloning and expressing the polypeptide or a library of polypeptides using synthesis-based DNA; and determining the activity of the polypeptide in an assay.

The present disclosure is based in part on studies that identify upregulation of markers in response to stimulation by an antigen (also referred to as activation induced markers) to detect antigen-specific immune cells, and uses thereof. The disclosure provides methods for identifying antigen-specific T cells produced in response to stimulation by an antigen.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

To provide polypeptides that bind to a transferrin receptor.SOLUTION: Provided herein are polypeptides that bind to a transferrin receptor, methods of producing such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.SELECTED DRAWING: None

A composition of matter comprising an isolated soluble polypeptide comprising an amino acid sequence of a Transferrin receptor protein 1 (TfR1) apical domain is disclosed, the soluble polypeptide being capable of binding an Arenavirus. A fusion protein comprising an amino acid sequence of a TfR1 apical domain and an amino acid sequence of IgG Fc, the fusion protein capable of binding an Arenavirus, is also disclosed.

The application describes anti-TfR antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are described. Also described are conjugates and fusion constructs containing the anti-TfR antibody or antigen-binding fragment thereof coupled to a therapeutic or diagnostic agent, such as a second antibody and antigen- binding fragment thereof, for treating or detecting a neurological disorder and / or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.

Disclosed are useful compositions of mixed lineage kinase domain-like (MLKL) derived fusion constructs and their methods of use in cellular depletion therapies. Embodiments of the present disclosure provide a chimeric cell death protein that induces immunogenic cell death in various types of cancers and also has applications in viral infection. The present disclosure also provides different methods of delivering the disclosed compositions or fusion constructs to a subject with cancer or tumor.

The invention mainly belongs to the technical field of tumor immunology, and specifically relates to a novel bladder cancer marker AG‑CD71 and an anti-AG‑CD71 monoclonal antibody ABC71. The human bladder cancer marker AG-CD71 of the present invention is an abnormally glycosylated transferrin receptor TFRC, and the abnormally glycosylated transferrin receptor TFRC means that TFRC carries an antigenic epitope The carbohydrate structure Fuca1‑4(GlcNAcb1‑3)[6OSO3]GlcNAc; and provide an antibody against the human bladder cancer marker AG‑CD71, the antibody is a specific anti-human bladder cancer AG‑CD71 monoclonal antibody Cloning antibody ABC71, the monoclonal antibody is secreted by the hybridoma cell line with the preservation number of CGMCC No.14312. Cellular and histological levels prove that: ABC71 specifically recognizes human bladder cancer cells and human bladder cancer tissues. Anti-human bladder cancer monoclonal antibody ABC71, the antibody has a strong positive reaction with human bladder cancer tissue, but a negative reaction with human normal bladder tissue.

The present invention provides polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition toa BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portionsof the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.

The invention discloses a reagent and a method for editing a pig CD71 gene, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to edit the pig CD71 gene. The reagent for editing the pig CD71 gene disclosed by the invention contains sgRNA, and the target sequence of the sgRNA is SEQ ID No.5 or SEQ ID No.2 in a sequence table. The sgRNA disclosed by the invention can specifically recognize a third exon region of the pig CD71 gene, the pig CD71 gene can be edited by utilizing a CRISPR / Cas9 system, and the cutting efficiency of the pig CD71 gene can reach 44.14%. The method can be applied to gene function research, disease-resistant breeding and the like of pig cells or individuals.

Methods of treating a subject having a lysosomal storage disease are provided, comprising engineering Lin-hematopoietic stem and / or progenitor cells to obtain engineered erythrocytes expressing a polypeptide, where the polypeptide may be alpha-GAL A or GRHPR. Also provided are methods of producing erythrocytes from Lin-hematopoietic stem and / or progenitor cells in vitro, erythrocytes produced by the methods, and compositions comprising the erythrocytes.

The present disclosure relates to targeted bispecific transferrin receptor 1 (TfR-1) antibodies and methods of use thereof. In particular, provided herein are oligodendrocyte- and neuron-targeting bispecific TfR-1 antibodies and methods of use thereof.

Provided are anti-TFR1 antibodies or antigen-binding fragments thereof, multispecific antibodies comprising the same, as well as preparation methods and uses thereof.

The present invention relates to a method for constructing a TFRC humanized mouse model, comprising: (1) constructing a targeting vector expressing a humanized TFRC gene; (2) designing and obtaining a sgRNA targeting the mouse TFRC gene; (3) co-injecting or co-electroporating the targeting vector, sgRNA, and Cas9 protein into the cytoplasm or nucleus of a mouse fertilized egg, transplanting the fertilized egg into a pseudopregnant mouse, performing genotyping on the pseudopregnant offspring, and screening for positive F0 mice in which the correct humanized fragment was successfully inserted; and (4) breeding the F0 mice with background mice to obtain F1 mice, and screening for a TFRC humanized mouse model. The TFRC humanized mouse constructed by the present invention has application value in fields such as oncology and immunology.

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA in a cell or animal, and in certain instances reducing the amount of PLN protein in a cell or animal. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to treat cardiomyopathy, heart failure, or arrhythmia.